Suppr超能文献

串联质谱法在 1 型戊二酸血症新生儿筛查中的成本效益分析。

Newborn screening by tandem mass spectrometry for glutaric aciduria type 1: a cost-effectiveness analysis.

机构信息

Department of General Paediatrics, Division of Inherited Metabolic Diseases, Centre for Paediatric and Adolescent Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 430, Heidelberg 69120, Germany.

出版信息

Orphanet J Rare Dis. 2013 Oct 17;8:167. doi: 10.1186/1750-1172-8-167.

Abstract

BACKGROUND

Glutaric aciduria type I (GA-I) is a rare metabolic disorder caused by inherited deficiency of glutaryl-CoA dehydrogenase. Despite high prognostic relevance of early diagnosis and start of metabolic treatment as well as an additional cost saving potential later in life, only a limited number of countries recommend newborn screening for GA-I. So far only limited data is available enabling health care decision makers to evaluate whether investing into GA-I screening represents value for money. The aim of our study was therefore to assess the cost-effectiveness of newborn screening for GA-I by tandem mass spectrometry (MS/MS) compared to a scenario where GA-I is not included in the MS/MS screening panel.

METHODS

We assessed the cost-effectiveness of newborn screening for GA-I against the alternative of not including GA-I in MS/MS screening. A Markov model was developed simulating the clinical course of screened and unscreened newborns within different time horizons of 20 and 70 years. Monte Carlo simulation based probabilistic sensitivity analysis was used to determine the probability of GA-I screening representing a cost-effective therapeutic strategy.

RESULTS

Within a 20 year time horizon, GA-I screening averts approximately 3.7 DALYs (95% CI 2.9 - 4.5) and about one life year is gained (95% CI 0.7 - 1.4) per 100,000 neonates screened initially . Moreover, the screening programme saves a total of around 30,682 Euro (95% CI 14,343 to 49,176 Euro) per 100,000 screened neonates over a 20 year time horizon.

CONCLUSION

Within the limitations of the present study, extending pre-existing MS/MS newborn screening programmes by GA-I represents a highly cost-effective diagnostic strategy when assessed under conditions comparable to the German health care system.

摘要

背景

I 型戊二酸血症(GA-I)是一种罕见的代谢紊乱疾病,由谷氨酸酰辅酶 A 脱氢酶遗传性缺乏引起。尽管早期诊断和开始代谢治疗的预后相关性很高,以及以后的生活中具有额外的节省成本潜力,但只有有限的几个国家建议对 GA-I 进行新生儿筛查。到目前为止,只有有限的数据可以使医疗保健决策者评估对 GA-I 筛查进行投资是否物有所值。因此,我们的研究目的是通过串联质谱(MS/MS)评估对 GA-I 进行新生儿筛查的成本效益,与不在 MS/MS 筛查面板中包含 GA-I 的情况进行比较。

方法

我们评估了通过 MS/MS 对 GA-I 进行新生儿筛查与不将 GA-I 纳入 MS/MS 筛查的替代方案相比的成本效益。开发了一个马尔可夫模型,模拟了在 20 年和 70 年不同时间范围内筛查和未筛查新生儿的临床过程。基于蒙特卡罗模拟的概率敏感性分析用于确定 GA-I 筛查代表成本效益治疗策略的概率。

结果

在 20 年的时间范围内,GA-I 筛查可避免约 3.7 DALYs(95%CI 2.9-4.5),并在每 10 万筛查新生儿中获得约 1 个生命年(95%CI 0.7-1.4)。此外,在 20 年的时间范围内,筛查计划为每 10 万筛查新生儿总共节省约 30682 欧元(95%CI 14343 至 49176 欧元)。

结论

在本研究的限制范围内,当根据与德国医疗保健系统可比的条件评估时,通过 GA-I 扩展现有的 MS/MS 新生儿筛查计划是一种具有高度成本效益的诊断策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bfb/4015693/9e3f598bf82e/1750-1172-8-167-1.jpg

相似文献

2
The M405V allele of the glutaryl-CoA dehydrogenase gene is an important marker for glutaric aciduria type I (GA-I) low excretors.
Mol Genet Metab. 2016 Sep;119(1-2):50-6. doi: 10.1016/j.ymgme.2016.06.012. Epub 2016 Jul 1.
3
Renal insufficiency mimicking glutaric acidemia type 1 on newborn screening.
Pediatr Int. 2018 Jan;60(1):67-69. doi: 10.1111/ped.13438. Epub 2017 Dec 14.
4
Evaluation of the first 5 years of a glutaric aciduria type I neonatal screening programme in Asturias.
An Pediatr (Engl Ed). 2024 May;100(5):318-324. doi: 10.1016/j.anpede.2024.04.011. Epub 2024 May 6.
5
Diagnosis, treatment and outcome of glutaric aciduria type I in Zhejiang Province, China.
Med Sci Monit. 2011 Jul;17(7):PH55-9. doi: 10.12659/msm.881834.
6
Is Expanded Newborn Screening Adequate to Detect Indian Biochemical Low Excretor Phenotype Patients of Glutaric Aciduria Type I?
Indian J Pediatr. 2019 Nov;86(11):995-1001. doi: 10.1007/s12098-019-03017-z. Epub 2019 Jul 13.
7
Selective screening for inborn errors of metabolism by tandem mass spectrometry at Sohag University Hospital, Egypt.
Arch Pediatr. 2022 Jan;29(1):36-43. doi: 10.1016/j.arcped.2021.11.002. Epub 2021 Nov 27.
9
Experiences during newborn screening for glutaric aciduria type 1: Diagnosis, treatment, genotype, phenotype, and outcomes.
J Chin Med Assoc. 2017 Apr;80(4):253-261. doi: 10.1016/j.jcma.2016.07.006. Epub 2017 Mar 13.
10
Extended newborn screening: an update for the general paediatrician.
J Paediatr Child Health. 2012 Feb;48(2):E68-72. doi: 10.1111/j.1440-1754.2011.02199.x. Epub 2011 Oct 21.

引用本文的文献

1
Wilson and Jungner Revisited: Are Screening Criteria Fit for the 21st Century?
Int J Neonatal Screen. 2024 Sep 13;10(3):62. doi: 10.3390/ijns10030062.
3
[Evaluation and optimization of newborn screening by structured long-term follow-up-using the example of inherited metabolic diseases].
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2023 Nov;66(11):1249-1258. doi: 10.1007/s00103-023-03772-7. Epub 2023 Oct 10.
5
Rare Disease Registries Are Key to Evidence-Based Personalized Medicine: Highlighting the European Experience.
Front Endocrinol (Lausanne). 2022 Mar 4;13:832063. doi: 10.3389/fendo.2022.832063. eCollection 2022.
8
Glutaric Aciduria Type 1: A Case Report and Review of Literature.
J Pediatr Intensive Care. 2021 Mar;10(1):65-70. doi: 10.1055/s-0040-1709704. Epub 2020 Apr 17.

本文引用的文献

1
Glutaric aciduria type I: outcome of patients with early- versus late-diagnosis.
Eur J Paediatr Neurol. 2013 Jul;17(4):383-9. doi: 10.1016/j.ejpn.2013.01.003. Epub 2013 Feb 5.
3
Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 1. From blood spot to screening result.
J Inherit Metab Dis. 2012 Jul;35(4):603-11. doi: 10.1007/s10545-012-9483-0. Epub 2012 May 3.
6
Diagnosis and management of glutaric aciduria type I--revised recommendations.
J Inherit Metab Dis. 2011 Jun;34(3):677-94. doi: 10.1007/s10545-011-9289-5. Epub 2011 Mar 23.
7
Use of guidelines improves the neurological outcome in glutaric aciduria type I.
Ann Neurol. 2010 Nov;68(5):743-52. doi: 10.1002/ana.22095.
8
Projected costs, risks, and benefits of expanded newborn screening for MCADD.
Pediatrics. 2010 Feb;125(2):e286-94. doi: 10.1542/peds.2009-0605.
9
Dynamic changes of striatal and extrastriatal abnormalities in glutaric aciduria type I.
Brain. 2009 Jul;132(Pt 7):1764-82. doi: 10.1093/brain/awp112. Epub 2009 May 11.
10
Economic evaluation of tandem mass spectrometry newborn screening in Australia.
Pediatrics. 2009 Feb;123(2):451-7. doi: 10.1542/peds.2008-0911.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验